The FDA has lifted the partial clinical hold on MediLink Therapeutics’ Phase 1 trial for BNT326/YL202, a HER3-targeting antibody-drug conjugate (ADC). This decision, announced on August 15, follows ...
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; ...
SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, ...
SAN ANTONIO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for an antibody drug conjugate (ADC) that shows ...
After penning a couple of antibody-drug conjugate (ADC) deals in 2023, BioNTech has returned to MediLink Therapeutics to further pad out its portfolio. This time, BioNTech is handing over $25 million ...
SHANGHAI--(BUSINESS WIRE)--Pacific Prime, a leading intermediary of international health insurance and employee benefits solutions, is proud to announce that it has been honored with the prestigious ...
The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech-partnered antibody-drug conjugate (ADC) that saw three fatalities after the companies confirmed that only lower ...
SUZHOU, China, May 26, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic ...
Presentation by the Chairperson of the Meeting, Lead Investigator Professor Li Zhang, said that "ADC is currently a highly anticipated field, and the data generated from the early international ...
MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global pharmaceutical company, according to people familiar with the situation. MediLink is ...
The decision follows complete response data, including data analysis, updated documentation, and additional risk mitigation measures. The FDA hold stemmed from concerns over dose-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results